Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rocket Pharmaceuticals, Inc.    RCKT

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 19.88 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is close to a major daily resistance at USD 29.14, which should be gotten rid of so as to gain new appreciation potential.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
ROCKET PHARMACEUTICALS, INC..23.48%1 551
-
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097
GENMAB A/S49.17%22 988
BIONTECH SE161.78%21 124
HUALAN BIOLOGICAL ENGINEERI..89.62%13 988
MYOKARDIA, INC.205.92%11 889
-
ARGENX SE45.54%11 712
SAREPTA THERAPEUTICS, INC.6.73%10 813
NEUROCRINE BIOSCIENCES, INC..-7.89%9 233
ASCENDIS PHARMA A/S14.83%8 499
MIRATI THERAPEUTICS, INC.39.84%8 026
EXELIXIS, INC.26.50%6 888
More Results
Financials (USD)
Sales 2020 - - -
Net income 2020 -105 M - -
Net cash 2020 286 M - -
P/E ratio 2020 -15,1x
Yield 2020 -
Capitalization 1 551 M 1 551 M -
EV / Sales 2020 -
EV / Sales 2021 134x
Nbr of Employees 79
Free-Float 91,0%
Upcoming event on ROCKET PHARMACEUTICALS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes